

## Cavrotolimod sodium

Cat. No.:	HY-139785A
Molecular Formula:	$C_{300}H_{399}N_{71}Na_{24}O_{161}P_{26}S_{23}$
Molecular Weight:	9670.31
Target:	Toll-like Receptor (TLR)
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

## Cavrotolimod (sodium)

### BIOLOGICAL ACTIVITY

#### Description

Cavrotolimod sodium is an immunostimulatory spherical nucleic acid (SNA) modified with type B CpG oligonucleotides designed to agonize TLR9 and elicit immune responses useful in oncology applications.

### REFERENCES

- [1]. Daniel WL, Lorch U, Mix S, Bexon AS. A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation. *Front Immunol.* 2022;13:1073777.
- [2]. Rubatto M, Sciamarrelli N, Borriello S, et al. Classic and new strategies for the treatment of advanced melanoma and non-melanoma skin cancer. *Front Med (Lausanne).* 2023;9:959289.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA